Related Experiment Video
Updated: Jan 19, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Rituximab-induced serum sickness in multiple sclerosis patients
Andrew B Wolf1, Lana Zhovtis Ryerson2, Krupa Pandey3
1Department of Neurology, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO 80045 USA.
Serum sickness, a hypersensitivity reaction, can occur in multiple sclerosis patients treated with rituximab. Management strategies and alternative anti-CD20 therapies are discussed for this patient group.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Rituximab, an anti-CD20 monoclonal antibody, is a recognized therapy for multiple sclerosis.
- Serum sickness, a type III hypersensitivity reaction, has been linked to rituximab in other conditions like rheumatoid arthritis.
Observation:
- This study describes cases of serum sickness in multiple sclerosis patients undergoing rituximab treatment.
- Observed symptoms include arthralgia, fever, and rash, consistent with serum sickness.
Findings:
- Rituximab-associated serum sickness is a potential adverse event in multiple sclerosis management.
- Effective management protocols for serum sickness in this context are crucial.
Implications:
- Understanding and managing serum sickness is vital for the continued use of anti-CD20 therapies.
- Alternative anti-CD20 monoclonal antibodies may be considered for patients experiencing rituximab-induced serum sickness.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease I: Introduction

